WEBULL
News
CRIS
1.030
+13.11%
0.119
Weekly Report: what happened at CRIS last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at CRIS last week (0119-0123)?
Weekly Report · 01/26 09:54
Weekly Report: what happened at CRIS last week (0112-0116)?
Weekly Report · 01/19 09:58
Curis Targets BTKi-Exposed CLL With New Emavusertib Combo Trial: What Investors Should Watch
TipRanks · 01/15 16:32
CURASIGHT ANNOUNCES ENCOURAGING PRELIMINARY DATA FROM PHASE 1 TRIAL EVALUATING FIRST-IN-CLASS RADIOPHARMACEUTICAL UTREAT IN HIGH-GRADE GLIOMAS®
Reuters · 01/12 18:03
Weekly Report: what happened at CRIS last week (0105-0109)?
Weekly Report · 01/12 09:56
CURIS ANNOUNCES CLOSING OF PRIVATE PLACEMENT TOTALING UP TO $80.8 MILLION IN GROSS PROCEEDS
Reuters · 01/09 13:00
Curis Announces PIPE Financing and Strategic Capital Strengthening
TipRanks · 01/08 11:31
Crude Oil Down 2%; ISM Services PMI Surges In December
Benzinga · 01/07 17:25
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 01/07 17:05
US Stocks Edge Higher; UniFirst Shares Fall After Q1 Results
Benzinga · 01/07 14:47
Curis prices private placement of $80.8M
Seeking Alpha · 01/07 14:38
Curis announces $80.8M private placement
TipRanks · 01/07 13:51
Curis Announces $80.8M PIPE Financing Backed By Healthcare-Focused Institutional Investors; Includes ~$20.2M Initial Proceeds,
Benzinga · 01/07 13:47
CURIS ANNOUNCES PRICING OF PRIVATE PLACEMENT TOTALING UP TO $80.8 MILLION IN GROSS PROCEEDS
Reuters · 01/07 13:45
Press Release: Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
Dow Jones · 01/07 13:45
Press Release: Curis Announces Pricing of Private -2-
Dow Jones · 01/07 13:45
Weekly Report: what happened at CRIS last week (1229-0102)?
Weekly Report · 01/05 09:53
Weekly Report: what happened at CRIS last week (1222-1226)?
Weekly Report · 12/29/2025 09:52
Weekly Report: what happened at CRIS last week (1215-1219)?
Weekly Report · 12/22/2025 09:52
More
Webull provides a variety of real-time CRIS stock news. You can receive the latest news about Curis through multiple platforms. This information may help you make smarter investment decisions.
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.